Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1862 results
May 2017
-
In The News
Novartis Access perspective: The key to fighting chronic disease in South-East Asia - young people
Harald Nusser, Head of Novartis Social Business, explains why educating young people is key to fighting chronic disease in South-East Asia. -
Story Discovery
Taking clinical trials to the next level through technology
Learn how Novartis is using technology to improve the oncology clinical trial process.
-
Press Release
Novartis exercises exclusive option agreement with Conatus for the treatment of NASH
Exclusive license for emricasan supports rapidly growing development portfolio in chronic liver diseases, including NASH Conatus has initiated the Phase IIb ENCORE-LF clinical trial with… -
In The News
Novartis Access perspective: How smart partnerships can help us fight chronic disease in Africa
Harald Nusser, Head of Novartis Social Business, talks about how the pharmaceutical industry can work with partners to overcome access issues in poor countries.
April 2017
-
Press Release
Novartis receives FDA approval for Rydapt® in newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of systemic mastocytosis (SM)
Approval in newly diagnosed FLT3-mutated AML represents the first new treatment in more than 25 years[1],[2] Rydapt treatment regimen in FLT3-mutated AML demonstrated a significant improvement… -
Press Release
Alcon announces EU launch of CyPass® Micro-Stent, a micro invasive glaucoma surgical device, to lower intraocular pressure (IOP) in patients with primary open-angle glaucoma
Now available in the UK, Germany, Italy and Spain, CyPass Micro-Stent is designed to significantly reduce intraocular pressure (IOP) CE indication has been expanded to allow patients to be… -
Press Release
Novartis delivered sales growth across all divisions (cc1) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued
Net sales grew 2% (cc, -1% USD), as growth drivers more than offset Gleevec/Glivec impact Cosentyx (USD 410 million, +136% cc) showing strong growth in all three indications Entresto (USD 84… -
Press Release
Novartis: ventes en progression (tcc1) dans toutes ses divisions; les moteurs de croissance, Cosentyx et Entresto inclus, compensent l'érosion due aux génériques; l'innovation toujours en plein essor
Chiffre d'affaires net en hausse de 2% (tcc, -1% en USD), car les moteurs de croissance ont plus que compensé l'impact de Gleevec/Glivec Cosentyx (USD 410 millions, +136% tcc):… -
Press Release
Novartis erzielt Umsatzsteigerungen in allen Divisionen (kWk1), wobei Wachstumstreiber wie Cosentyx und Entresto die Einbussen durch Generika mehr als wettmachen; Innovationsdynamik setzt sich fort
Der Nettoumsatz wächst um 2% (kWk, -1% USD), da die Wachstumstreiber die Einbussen bei Glivec/Gleevec mehr als wettmachen Cosentyx (USD 410 Millionen, +136% kWk) erzielt in allen drei Indikationen… -
Press Release
Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the US and Canada
Novartis and Amgen to co-commercialize AMG 334 (erenumab) in the US; Novartis to gain exclusive rights in Canada Novartis retains commercial rights in rest of world; Amgen retains commercial… -
Story Discovery
Saving tumor suppressors from the shredder
Novartis opens up a path of research to protect proteins that guard against cancer.
-
Press Release
Novartis real-world data at AAN confirms benefit of Gilenya® on four key measures of disease activity in relapsing MS
Over 16 months, more than 75% of patients on Gilenya had either no relapses, no new or enlarged MRI lesions or no disability progression; around 58% showed brain shrinkage levels broadly within the…